Payment overview · 2025
General Payments
$878.21
6 reported records · 2 companies
Healthcare provider profile · identity verified
Grace Chow, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JAMAICA, NY · NPI 1558379628
Verified facts
What the public records show
CMS Open Payments records show Grace Chow, MD received $878.21 in general payments during 2025 across 6 reported records.
ViiV Healthcare Company accounted for 71.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato, Rukobia.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $624.04 | 71.1% | 5 | 2025 |
| ZOLL Medical Corporation | Unresolved — no canonical attribution shown | $254.17 | 28.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $624.04 | 5 |
| Consulting Fee | $254.17 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Defibrillator Normalized: defibrillator |
Device | ZOLL Medical Corporation | $254.17 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $249.04 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $125.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 301 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 273 | 94 |
| Losartan Potassium | Losartan Potassium | 156 | 47 |
| Metformin Hcl | Metformin Hcl | 156 | 45 |
| Gabapentin | Gabapentin | 148 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 143 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 36 |
| Jardiance | Empagliflozin | 134 | 37 |
| Januvia | Sitagliptin Phosphate | 122 | 28 |
| Famotidine | Famotidine | 108 | 36 |
| Omeprazole | Omeprazole | 105 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 31 |
| Lisinopril | Lisinopril | 93 | 25 |
| Tivicay | Dolutegravir Sodium | 86 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 22 |
| Carvedilol | Carvedilol | 71 | 19 |
| Chlorthalidone | Chlorthalidone | 69 | 18 |
| Ozempic | Semaglutide | 64 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 62 | 18 |
| Meloxicam | Meloxicam | 62 | 21 |
| Ammonium Lactate | Ammonium Lactate | 61 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 16 |
| Glimepiride | Glimepiride | 58 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 18 |
| Descovy | Emtricitabine/Tenofov Alafenam | 54 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 11 |
| Ramipril | Ramipril | 54 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 52 | 20 |
| Simvastatin | Simvastatin | 52 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 18 |
| Valsartan | Valsartan | 46 | 12 |
| Montelukast Sodium | Montelukast Sodium | 44 | 15 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 42 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 41 | 18 |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | 12 |
| Furosemide | Furosemide | 40 | 12 |
| Dovato | Dolutegravir Sodium/Lamivudine | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 12 |
| Valacyclovir | Valacyclovir Hcl | 38 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Griseofulvin Ultramicrosize | Griseofulvin Ultramicrosize | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | 13 |
| Repaglinide | Repaglinide | 28 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 27 | 11 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 12 |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 16 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Erythromycin | Erythromycin Base In Ethanol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $878.21 · 6 records | ViiV Healthcare Company | CABENUVA, DOVATO, Defibrillator, RUKOBIA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ViiV Healthcare Company?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error